164 related articles for article (PubMed ID: 38267623)
21. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
22. Predictive Value of
Chen XJ; Ren AQ; Zheng L; Zheng ED
Front Immunol; 2021; 12():664847. PubMed ID: 33953726
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
[TBL] [Abstract][Full Text] [Related]
24. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
[TBL] [Abstract][Full Text] [Related]
25.
Yang D; Feng Y; Lu H; Chen K; Xu J; Li P; Wang T; Xia D; Wu Y
J Zhejiang Univ Sci B; 2023 Feb; 24(2):143-156. PubMed ID: 36751700
[TBL] [Abstract][Full Text] [Related]
26.
Ji W; Niu X; Yu Y; Li Z; Gu L; Lu S
Front Immunol; 2022; 13():955800. PubMed ID: 36405701
[TBL] [Abstract][Full Text] [Related]
27. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
28. Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
Gao G; Cui L; Zhou F; Jiang T; Wang W; Mao S; Wu F; Jiang F; Zhang B; Bei T; Xie W; Zhang C; Zhang H; Gao C; Zhao X; Bai Y; Zhou C; Ren S
Int J Cancer; 2023 Jan; 152(1):79-89. PubMed ID: 36062503
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
30. Predictive Value of the
Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
Front Immunol; 2021; 12():643282. PubMed ID: 34421886
[TBL] [Abstract][Full Text] [Related]
31. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
[TBL] [Abstract][Full Text] [Related]
32. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Chen P; Long J; Zhang J; Xie F; Wu W; Tian Z; Zhang S; Yu K
Inflamm Res; 2024 Feb; 73(2):263-276. PubMed ID: 38200372
[TBL] [Abstract][Full Text] [Related]
33. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
34. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.
An F; Zhang W; Guo Y; Shi F; Kong Y; Tang L; Han C; Wang Q
Aging (Albany NY); 2023 Aug; 15(15):7476-7495. PubMed ID: 37535001
[TBL] [Abstract][Full Text] [Related]
35.
de Kouchkovsky I; Zhang L; Philip EJ; Wright F; Kim DM; Natesan D; Kwon D; Ho H; Ho S; Chan E; Porten SP; Wong AC; Desai A; Huang FW; Chou J; Oh DY; Pruthi RS; Fong L; Small EJ; Friedlander TW; Koshkin VS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980590
[TBL] [Abstract][Full Text] [Related]
36. HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.
Li L; Tianrui K; Chunlei L; Zhendong Q; Xiaoyan C; Wenhong D
Aging (Albany NY); 2023 Aug; 15(16):7997-8012. PubMed ID: 37595251
[TBL] [Abstract][Full Text] [Related]
37. Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy.
Cui S; Chen T; Zhao Y; Xiao Z; Liu M; Huang X; Cao S; Zhou R; Li Y; Huo X; Wang N
Curr Cancer Drug Targets; 2024; 24(5):501-509. PubMed ID: 38804343
[TBL] [Abstract][Full Text] [Related]
38.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
39. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments.
Wang DX; Long JY; Li RZ; Zhang DL; Liu H; Liu J; Tian JC; Li H; Liu J; Zhao HT; Li T
Mol Cancer; 2024 Jan; 23(1):15. PubMed ID: 38225603
[TBL] [Abstract][Full Text] [Related]
40. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
